

BioCirc at a glance

Who We Are

BioCirc is a circular bioeconomic company, founded in 2021, that abates CO2 emissions by producing green energy in the form of electricity, gas, fuel and heat in integrated energy clusters.

We act as a one-stop-shop for municipalities that need to accelerate the green transition, and our concept ensures true circularity, job creation and a renewable energy transition locally.

We have offices in Middelfart and Copenhagen and employ more than 300 people.

BioCirc's ownership consists of several entities, including DLG Group, a cooperative and its 25,000 Danish farmers.

What We Do

BioCirc has an extensive biomethane production. We own and operate eight biogas plants in Denmark, representing one of the largest biogas productions globally.

With biogas production at its core, we develop, own and operate circular energy clusters and already have large scale projects in mature development.

Our current biogas operations and future energy clusters act as key levers to reach a full and fair green transition, and our solutions address decarbonisation of some of the hardest sectors to transform.



Best-in-class developer, owner and operator of green energy clusters, displacing the use of fossil energy locally



Help local communities implementing a full and fair green transition today, to ensure our children have a safer and more sustainable future





Main events in the last four quarters

Q3 2024

Biocirc successfully issued a **EUR 70 million senior unsecured bond** to support continued growth

Biocirc secured **environmental permit for Vinkel Biogas** expansion, allowing more than doubling of its biomass handling capacity

In September, Vinkel Solar park obtained a building permit, enabling the construction of the new solar facility

Inhouse certificate trading team in place to handle the majority of certificate trades from October 2024, improving transparency in market prices, enhancing financial stability, and reducing trader dependency

BioCirc and DLG are launching a new sandwashing technology designed to revolutionise manure management in Denmark's Dairy sector. This standalone, plugand-play system allows farmers using sand in cow bedding to easily prepare manure for biogas production



Vinkel solar park

Q4 2024

BioCirc's signs its first Power Purchase Agreement (PPA) with DLG. The 10-year agreement will see DLG Group sourcing 50% of its annual electricity consumption in Denmark – equivalent to approximately 60 GWh. The PPA is based on production from two new solar parks, which are expected to be operational in 2025 and 2026

BioCirc joins Greensand Future as the largest biogenic CO₂ supplier. Over the course of the project, BioCirc will contribute up to 1 million tons of permanently stored biogenic CO₂. Our collaboration with INEOS Energy and Greensand Future ensures that captured biogenic CO₂ will be securely stored 1,800 meters beneath the seabed in the Nini West reservoir

BioCirc acquires DLG's biomass trading operations, including supplier and customer agreements, strengthening our role in the procurement and distribution of biomass for biogas plants



BioCircs CCS project

Q1 2025

In January 2025, BioCirc announced a partnership with cattle producers in Alberta to co-develop its first international biogas facility. The plant will convert manure and household waste into renewable gas, create local jobs, and be co-owned by farmers—reflecting BioCirc's commitment to inclusive, locally anchored energy solutions

BioCirc secured the entire value chain for Denmark's first biogenic CO₂ storage project through agreements with Pentair Union Engineering, Koldkur Transport, and Puro.earth – from capture and liquefaction to transport, storage, and verified climate impact

In March 2025, BioCirc successfully secured more than DKK 300 million in additional capital from existing shareholders and employees. This strengthens BioCirc's financial position and demonstrates strong commitment to the company's mission and strategy



BioCircs CCS project (value chain)

Q2 2025

Biocirc secured financing for the CCS projects, with final agreement signed in July, and for the expansion of Vinkel Biogas, amounting to a total of EUR 66 million. This includes a EUR 27.5 million loan from Nordic Investment Bank under the InvestEU program to co-finance the development of carbon capture and liquefaction infrastructure at five biogas plants, enabling safe transport and permanent storage through Project Greensand

In June, BioCirc published its prospectus for the listing of its senior unsecured bonds and was approved for admission to trading and official listing on Nasdaq Copenhagen

BioCirc has published its first annual report prepared in accordance with International Financial Reporting Standards (IFRS)

BioCirc has received approval for the three power projects: A 140 MW solar park in Brønderslev, a 60-hectare solar park in Kvorning, and three wind turbines combined with a 20-hectares of solar park in Sjørring



Financial performance for H1 2025

BioCirc delivered revenue of DKK 870 million and adjusted EBITDA of DKK 113 million in H1 supported by strong gas price development in Q1, positive hedging strategy and robust certificate sales.

H1 Financial Performance

In Q2 2025, BioCirc delivered an increase in both revenue and adjusted EBITDA Adjusted EBITDA increased slightly to DKK 63 million in Q2 2025 compared to compared to Q1, despite lower gas prices. Revenue rose to DKK 443 million in Q2 2025, slightly above DKK 427 million in Q1 2025 and significantly higher than DKK 348 million in Q2 2024. The company's hedging strategy continued to prices during the quarter, partly offset by higher project expenses within EPC support realised revenue, while certificate sales provided an additional boost, including DKK 15 million from higher-than-expected realised prices on certificates related to the previous year. Adjusted EBITDA increased to DKK 63 million, up from DKK 50 million in Q1, underpinned by certificate sales and operational robustness. For the first half of 2025, BioCirc achieved revenue of DKK 870 million, relative to DKK 694 million in H1 2024. Adjusted EBITDA reached DKK 113 million in H1 2025, compared to DKK 72 million in H1 2024, reflecting stronger operations, favourable hedging, and positive developments in the certificate market. The secured financing further solidified BioCirc's financial position for the remaining development activities.

Revenue

BioCirc reinforced the positive trajectory established in Q1, reporting Q2 2025 revenue of DKK 443 million, slightly above Q1 2025 of DKK 427 million and significantly higher than Q2 2024 of DKK 348 million. Although average gas prices were lower in Q2 2025 compared to the previous three quarters, the hedging strategy contributed positively to realised revenue. This effect was further supported by favorable certificate sales in Q2 2025, including DKK 15 million from settlement of prior-year certificates sold by an external trader at higher-than-expected prices. BioCirc achieved H1 2025 revenue of DKK 870 million, a substantial increase from DKK 694 million in H1 2024, representing a year-over-year growth of +25%.

Gross profit

Gross profit amounted to DKK 215 million in Q2 2025, slightly down from DKK 224 in Q1 2025. The change originates from revenue of DKK 443 million in Q2 2025 compared to Q1 2025 of DKK 427 million offset by corresponding higher cost of DKK 230 million in Q2 2025, relative to DKK 205 million in Q1 2025.

Adjusted EBITDA

DKK 50 million in Q1 2025. The development within "other expenses" reflected a significant reduction in energy costs, driven by lower gas and electricity and a minor increase in administrative and sales costs. Overall, BioCirc continued to build on the solid adjusted EBITDA delivered in Q1, demonstrating resilience despite lower gas prices, with results underpinned by strong certificate sales and robust operations.

In H1 2025, BioCirc delivered adjusted EBITDA of DKK 113 million, a significant increase relative to DKK 72 million in H1 2024, representing year-on-year growth of +53%. The focus on strengthening operations and insourcing trading activities has further supported performance, resulting in reported EBITDA of DKK 63 million.

Liquidity


BioCirc ended the guarter with DKK 191 million in cash and cash equivalents, compared to DKK 349 million in Q1 2025, reflecting self-financing of ongoing development projects. The recently secured EUR 66 million financing for the CCS projects and Vinkel expansion is expected to ensure funding for the remaining costs for those two projects.

Future Outlook


BioCirc enters O3 with a solid financial base, supported by the secured financing for the CCS projects and the expansion of Vinkel Biogas. BioCirc remains focused on project execution, with the CCS progressing as planned and operations expected to commence in Q2 2026.

As highlighted in Q1, BioCirc has hedged more than half of its expected 2025 gas production at attractive average prices. This position continues to provide strong revenue visibility and a favourable margin compared to current spot prices and futures, which are trading around DKK 2.7-3.0 per Nm³. The hedges underpin a firm earnings floor and are expected to support stable performance in the guarters ahead, with production volumes remaining steady on the back of high uptime and efficient operations.

Financial highlights H1 2025. DKK












Gas prices dropped below the subsidy floor in April, then rebound and

spiked end of Q2, before stabilizing at Q3 average of ~2,8 DKK/Nm³



Source: European Energy Exchange AG (21/08/2025)





Consolidated income statement

Amounts in DKKm	Note	Q2 2025	Q1 2025	H1 2025	Q2 2024	Q1 2024	H1 2024
Revenue		442.8	426.9	869.7	347.7	346.5	694.2
Other income		2.5	2.5	5.0	4.7	4.8	9.5
Changes in inventories of finished goods and work in progress		(7.0)	11.1	4.1	9.4	9.4	18.8
Raw materials and consumables used		(222.89)	(216.5)	(439.4)	(175.3)	(212.5)	(387.8)
Gross profit		215.4	224.0	439.4	186.5	148.1	334.6
Employee benefits expense		(53.7)	(48.9)	(102.6)	(44.5)	(31.8)	(76.3)
Other expenses		(136.2)	(137.3)	(273.5)	(142.5)	(97.1)	(239.6)
Operating profit before amortisation, depreciation and impairment (EBITDA)		25.5	37.8	63.3	(0.5)	19.2	18.7
Depreciation, amortisation and impairment		(60.4)	(47.7)	(108.1)	(48.4)	(50.6)	(99.0)
Operating profit		(34.9)	(9.9)	(44.8)	(48.9)	(31.4)	(80.3)
Financial income		1.2	1.1	2.3	2.8	0.0	2.8
Financial expenses		(26.6)	(29.0)	(55.6)	(36.4)	(8.0)	(44.4)
Profit (loss) before income tax		(60.3)	(37.8)	(98.1)	(82.5)	(39.4)	(121.9)
Income tax expense		10.3	13.0	23.3	11.4	4.1	15.5
Profit (loss) for the period		(50.0)	(24.8)	(74.8)	(71.1)	(35.3)	(106.4)

Profit is attributable to:

Owners of BioCirc Group Holding ApS



Consolidated balance sheet

Amounts in DKKm	Note	30 June 2025	31 december 2024
Assets			
Non-current assets			
Goodwill		1.227,2	1.199,6
Other intangible assets		170,6	176,6
Intangible assets		1.397,8	1.376,2
Property, plant, equipment and right-of-use assets		3.586,8	3.405,3
Other non-current financial assets		0,5	1,1
Total non-current assets		4.985,1	4.782,6
Current assets			
Inventories		159,0	151,5
Trade and other receivables		281,8	262,7
Prepayments		134,0	57,2
Cash and cash equivalents		191,4	244,0
Total current assets		762,3	715,4
Total assets		5.751,3	5.498,0



Consolidated balance sheet

Amounts in DKKm	Note	30 June 2025	31 december 2024
Equity			
Share capital		14.2	12.5
Other paid-in capital		3,591.2	3,261.0
Retained earnings		(392.6)	(320.1)
Total equity		3,212.8	2,953.4
Liabilities			
Non-current liabilities			
Mortgages and bank debt		1,065.5	974.5
Bonds		471.6	470.6
Lease liabilities		140.4	105.9
Deferred income		218.1	213.7
Contract liabilities		0.0	0.0
Provisions		17.8	19.6
Deferred tax liabilities		203.3	238.2
Other non-current financial liabilities		0.0	0.0
Total non-current liabilities		2,116.7	2,022.5
Current liabilities			
Mortgages and bank debt		115,9	134,2
Trade and other payables		223,0	307,5
Lease liabilities		24,2	22,1
Deferred income		0,1	8,9
Contract liabilities		58,4	49,4
Income tax payable		0,2	0,0
Total current liabilities		421,8	522,1
Total liabilities		2.538,5	2.544,6
Total equity and liabilities		5.751,3	5.498,0



Consolidated statement of changes in equity

Amounts in DKKm	Note	Contributed capital	Other paid in capital	Retained earnings	Total
As at 1 January 2025		12.5	3,261.0	(320.1)	2,953.4
Profit for the period		0.0	0.0	(74.8)	(74.8)
Other comprehensive income		0.0	0.0	0.0	0.0
Total comprehensive income		12.5	3,261.0	(394.9)	2,878.6
Transactions with owners					
Capital increase		1.7	330.2	0.0	331.9
Share-based payments		0.0	0.0	2.3	2.3
Total transactions with owners		1.7	330.2	2.3	334.2
Total equity 30 June 2025		14.2	3,591.2	(392.6)	3,212.8

Amounts in DKKm	Note	Share capital	Other paid-in capital	Retained earnings	Total
As at 1 January 2024		11.6	2,865.3	(129.4)	2,747.5
Profit for the period		0.0	0.0	(107.2)	(107.2)
Other comprehensive income		0.0	0.0	0.0	0.0
Total comprehensive income		11.6	2,865.3	(236.6)	2,640.3
Transactions with owners					
Capital increases		0.6	0.0	0.0	0.6
Share-based payments		0.0	0.0	2.2	2.2
Total transactions with owners		0.6	0.0	2.2	2.8
Total equity 30 June 2024		12.2	2,865.3	(234.4)	2,643.1



Consolidated cash flow statement

Amounts in DKKm	Note	H1 2025	H1 2024
Operating profit before amortization, depreciation and impairment (EBITDA)		63,3	18,7
Adjustments to reconcile EBITDA to net cash flows:			
Other non-cash adjustments		2,3	2,2
Total adjustments to reconcile EBITDA to net cash flows		2,3	2,2
Working capital changes		24,3	286,9
Financial income received		2,3	2,8
Financial expenses paid		(55,6)	-44,4
Corporation tax paid		0,0	-0,2
Net cash flow from operating activities		36,6	266,0
Purchase of property, plant and equipment		(403,0)	(91,3)
Sale of property, plant and equipment		3,9	1,4
Asset acquisitions, net of cash acquired		0,0	(147,3)
Acquisition of subsidiaries, net of cash acquired		(0,1)	(167,5)
Development expenditures capitalized		(27,7)	(51,7)
Net cash flows from investing activities		(426,9)	(456,4)
Proceeds from mortgages and bank debt		81,0	174,0
Repayment of mortgages and bank debt		(64,8)	(100,5)
Proceeds from bonds		0,0	0,0
Payment of principal portion of lease liabilities		(10,6)	(12,1)
Capital increase		332,0	0,0
Net cash flows from financing activities		337,6	61,4
Net increase in cash and cash equivalents		(52,7)	(129,0)
Cash and cash equivalents, beginning of the period		244,1	165,2
Cash and cash equivalents at the end of the period		191,4	36,2



Notes

- 1. Basis of reporting
- 2. Segment information
- 4. Revenue
- 5. Significate items
- 6. Tax for the period
- 7. Property, plant and equipment
- 8. Financial assets and financial liabilities
- 9. Capital increases
- 10. Events after the reporting period



1. Basis of reporting

BioCirc Group Holding ApS is a limited liability company incorporated and domiciled in Denmark. Its registered office address is Amaliegade 22, 1., 1256 København K.

The consolidated financial statements for the period ended 30 June 2025 include BioCirc Group Holding ApS (the Parent) and its subsidiaries (collectively, the Group).

The interim consolidated financial statements has been prepared in accordance with the International Financial Reporting Standards (IFRS Accounting Standards), IAS 34 Interim Financial Reporting, as adopted by the EU. The interim report has not been audited or reviewed by the Group's independent auditors.

The interim consolidated financial statements for the six months ended 30 June 2025 are a condensed set of financial statements, as they do not include all the information and disclosures required by the annual consolidated financial statements.

These interim consolidated financial statements have been prepared using the same accounting policies and methods of computation as outlined in the annual report as of 31 December 2024. Accordingly, this interim report should be read in conjunction with the consolidated financial statements for the year ended 31 December 2024. There have been no changes to the accounting policies or methods of computation.



2. Segment information

Descriptions of segments

Details on each operating segment of the Group are provided below. There are no differences from the last consolidated annual report in the basis of segmentation or the measurement of segment profit or loss.

Operating segment	Primary activities
Biogas	The biogas segment encompasses the entire value chain of the Group's biogas operations, including biogas production facilities, supply chain entities, and certain trading activities related to biogas. Revenue for this segment is primarily derived from the sale of biogas and certificates, which comprises the vast majority of the Group's revenue.
EPC	The EPC segment comprises the activities of North-Tec, a Germany-based entity acquired in 2024, specializing in Engineering, Procurement, and Construction (EPC) of biogas plants. Revenue for this segment is primarily derived from construction contracts related to the expansion, upgrade, and maintenance of biogas plants, as well as other services.
All other segments	All other segments comprise business areas that, at the Group level, as of the preparation of these consolidated financial statements, are not considered significant to daily operations. This grouping also includes the Group's support functions, which exist solely to support core activities and do not independently contribute to financial performance. Revenue from this grouping of segments primarily consists of intersegment revenue with the biogas segment as the counterparty, including management fees and other internal transactions. Currently, external revenue is insignificant.



2. Segment information

Information about profit or loss

Q2 2025	Diagna	EDC	All other segments	Total sogments As	divistments and climinations	Consolidated		
Amounts in DKKm	Biogas	EPC	All other segments	Total Segments At	Total segments Adjustments and eliminations			
Revenue								
External customers	401,1	38,7	3,0	442,8	0,0	442,8		
Inter-segment	0,0	2,5	14,3	16,8	(16,8)	0,0		
Total	401,1	41,2	17,3	459,6	(16,8)	442,8		
Other income	2,5	0,0	0,0	2,5	0,0	2,5		
Costs of goods solds	(248,6)	(23,3)	0,0	(271,9)	2,3	(269,6)		
Operating costs	(73,4)	(3,0)	(2,1)	(78,5)	0,5	(78,0)		
Selling, general, and administrative costs	(24,5)	(13,6)	(47,9)	(86,0)	13,8	(72,2)		
EBITDA	57,1	1,3	(32,7)	25,7	(0,2)	25,5		
Normalized EBITDA	82,2	1,3	(20,3)	63,2	(0,2)	63,0		

Q2 2024	Diama	FDC	All other comments	Total comments	Adinatus and aliminations	Consolidated
Amounts in DKKm	Biogas	EPC	All other segments	Total segments	Adjustments and eliminations	Consolidated
Revenue						
External customers	293,5	53,3	0,9	347,7	0,0	347,7
Inter-segment	0,0	4,0	34,7	38,7	(38,7)	0,0
Total Revenue	293,5	57,3	35,6	386,4	(38,7)	347,7
Other income	4,7	0,0	0,0	4,7	0,0	4,7
Costs of goods solds	(171,1)	(42,5)	0,0	(213,6)	0,0	(213,6)
Operating costs	(72,4)	(2,2)	(1,6)	(76,2)	0,1	(76,1)
Selling, general, and administrative costs	(24,3)	(12,3)	(39,5)	(76,1)	12,9	(63,2)
EBITDA	30,4	0,3	(5,5)	25,2	(25,7)	(0,5)
Normalized EBITDA	42.0	0.3	12.6	54.9	(25.7)	29.2



2. Segment information

Normalized EBITDA includes adjustments that the CODM believes provide a more accurate representation of the Group's operational performance. This is the figure that the CODM regularly uses to assess the Group's performance. It is adjusted for non-recurring events and transactions, such as transaction and other related costs, termination fees on certificate sales contracts, and compensation from legal disputes. Additionally, normalized EBITDA includes adjustments such as management fees from unconsolidated group entities, other income items not tied to biogas production, external certificate trader costs, expenses related to share-based payments, as well as other non-recurring items. Normalized EBITDA for all segments reconciles to the Group's profit before income tax as follows:

Reconciliations

Amounts in DKKm	H1 2025	H1 2024
Normalized EBITDA	112.9	73.5
Transaction and related costs	(2.1)	(11.6)
External certificate trader costs	(21.6)	(24.2)
Other income recognized from government grants	4.8	8.7
Other non-recurring items recognized in other income	0.0	0.0
Contract termination fees	0.0	0.0
Expense from prior period subsidy overcompensation	(8.7)	(5.9)
Compensation from legal settlement	0.0	0.0
Expenses related to share-based payments	(1.1)	(2.3)
Consulting fees related to IFRS and ESG advisory	(3.8)	(2.2)
Other adjustments	(17.1)	(17.3)
Operating profit before amortisation and depreciation (EBITDA)	63.3	18.7
Depreciation, amortisation and impairment	(108.1)	(99.0)
Financial income	2.3	2.8
Financial expenses	(55.6)	(44.4)
Profit before tax	(98.1)	(121.9)



4. Revenue

Disaggregation of revenue

The Group derives its revenue from the following streams:

Q2 2024 Amounts in DKKm		Biogas	3		EPC		All other segments	
Revenue type	Sale of gas	Sale of certificates	Government grants	Other	Construction contracts	Other	Other	Total revenue
Geographical regions								
Denmark	132.6	39.9	98.7	23.1	4.0	0.0	3.0	301.1
Other	39.7	67.2	0.0	0.0	33.4	1.4	0.0	141.7
Total revenue	172.2	107.1	98.7	23.1	37.3	1.4	3.0	442.8
Revenue recognised at a point in time	54.6	107.1	98.7	23.1	0.0	1.4	3.0	287.8
Revenue recognised over time	117.7	0.0	0.0	0.0	37.3	0.0	0.0	155.0
Total revenue	172.2	107.1	98.7	23.1	37.3	1.4	3.0	442.8

Q1 2024 Amounts in DKKm		Biogas					All other segments	
Revenue type	Sale of gas	Sale of certificates	Government grants	Other	Construction contracts	Other	Other	Total revenue
Geographical regions								
Denmark	117.3	55.3	96.1	24.8	0.0	0.0	0.9	294.4
Other	0.0	0.0	0.0	0.0	51.3	2.0	0.0	53.3
Total revenue	117.3	55.3	96.1	24.8	51.3	2.0	0.9	347.7
Revenue recognised at a point in time	117.3	55.3	96.1	24.8	0.0	2.0	0.9	296.4
Revenue recognised over time	0.0	0.0	0.0	0.0	51.3	0.0	0.0	51.3
Total revenue	117.3	55.3	96.1	24.8	51.3	2.0	0.9	347.7

Other revenue streams for the biogas segment primarily include revenue from ordinary sales contracts for the sale of biomaterial.

Other revenue streams for the EPC segment include asset management services and the sale of software for biogas plants.

Other revenue streams from the Group's remaining operating segments (presented as 'all other segments') consist primarily of lessor income and power sales, all of which are currently considered immaterial



5. Significate items

During the six months ended 30 June 2025, the Group's income statement was not affected by any significant items of an unusual nature or size.



6. Tax for the period

Tax is charged at 22% for the six months ended 30 June 2025, representing the best estimate of the average annual effective tax rate expected to apply for the full year, applied to the pre-tax income of the three-month period.



7. Property, plant and equipment

Amounts in DKKm	Total property, plant and equipment
Cost as at 1 January 2025	3,626.6
Additions	430.7
Transfers	0.0
Foreign currency adjustments	0.0
Disposals	(4.0)
Cost as at 30 June 2025	4,053.3
Depreciation and impairment as at 1 January 2025	(358.5)
Depreciation	(108.1)
Impairment	0.0
Foreign currency adjustments	0.0
Reversal of depreciation of assets disposed of	0.1
Depreciation and impairment as at 30 June 2025	(466.5)
Carrying amount as at 30 June 2025	3,586.8

Significant acquistions

Purchases of property, plant, and equipment amounted to DKKm 430.7 for the period, driven by the expansion of the Vinkel biogas facility, the establishment of the solar power plant in Vinkel, and the acquisitions of carbon capture and storage property, plant, and equipment.

Significant commitments

There have been no changes to the capital commitments as disclosed in the consolidated financial statements for the period ended 31 December 2024.



8. Financial assets and financial liabilities

Set out below is an overview of the carrying amounts financial assets and liabilities held by the Group:

Amounts in DKKm	30 June 2025	31 December 2024
Financial assets measured at amortised cost:		
Cash and cash equivalents	191.4	244.0
Trade and other receivables	281.8	262.7
Total financial assets	473.2	506.7
Amounts in DKKm	30 June 2025	31 December 2024
Financial liabilities measured at amortised cost:		
Trade and other payables	223.0	307.5
Trade and other payables	223.0	307.3
Mortgages and bank debt	1,181.4	1,108.7
· ·		
Mortgages and bank debt	1,181.4	1,108.7
Mortgages and bank debt Bonds	1,181.4 471.6	1,108.7 470.6

Management has determined that the carrying amounts of the financial instruments are a reasonable approximation of their fair values.

Issues and repayments of debt

Proceeds from new borrowings and repayments of existing borrowings during the six months ended 30 June 2025 are presented in the financing activities section of the condensed consolidated statement of cash flows. These movements are primarily driven by activities under the Group's bank debt, which mainly consists of credit facility agreements. There were no repurchases of debt during the period.



9. Capital increases

For the six months ended 30 June 2025, the Group had raised DKKm 332 million in cash through the issuance of new shares, primarily to existing shareholders and employees. The proceeds are primarily designated to fund significant strategic capital projects commencing or ongoing in 2025, including the major expansion of the Vinkel biogas plant, the development of an adjacent solar park, and the construction of five carbon capture plants across various locations.



10. Events after the reporting period

Start of July 2025, BioCirc signed EUR 33 million financing for the CCS projects including a EUR 27.5 million loan from Nordic Investment Bank under the InvestEU program to co-finance the development of carbon capture and liquefaction infrastructure at five biogas plants enabling safe transport and permanent storage through Project Greensand





Parent Company income statement

Income statement			
DKKm	Q2 2025	Q1 2025	H1 2025
Revenue	0.0	0.0	0.0
Direct costs	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0
Personnel cost	0.0	0.0	0.0
Administration and sales	(0.6)	(0.1)	(0.6)
Other cost	0.0	0.0	0.0
EBITDA	(0.6)	(0.1)	(0.6)
Depreciation of tangible assets	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0
EBIT	(0.6)	(0.1)	(0.6)
Net financial income	(60.5)	(50.5)*	(111.0)
EBT	(61.1)	(50.6)	(111.6)
Tax	0.1	0.0	0.1
Net Income	(60.9)	(50.6)	(111.5

^{*} Driven by change in accounting policies for depreciation



Parent Company balance sheet

Balance sheet		
DKKm	Q2 2025	Q1 2025
Shares in group companies	1,786.7	1,845.1*
Property, plant, and equipment	0.0	0.0
Development projects	0.0	0.0
Fixed assets	1,786.7	1,845.1
Inventory	0.0	0.0
Trade receivables	0.0	0.0
Receivables from group companies	1,613.9	1,368.7
Cash	105.1	287.7
Current assets	1,719.0	1,656.4
Assets	3,505.7	3,501.5

Balance sheet		
DKKm	Q2 2025	Q1 2025
Equity	2,970.6	2,691.2
Deferred tax	2.8	1.2*
Other provisions	0.0	0.0
Provisions	2.8	1.2
Interest bearing debt	516.4	516.0
Trade payables	1.2	1.2
Deferred income	0.0	0.0
Other payables	14.7	291.9
Equity and liabilities	3,505.7	3,501.5

^{*} Adjustment of closing balance 2024 originates from the approved 2024 annual report



Parent Company cash flow statement

Cash flow statement		
DKKm	Q2 2025	Q1 2025
Operating activities		
EBIT	(0.6)	(0.1)
Adjustment for non-cash items	0.0	0.0
Interest net and income from investments	(60.5)	(50.5)
Income tax paid	1.8	1.2
Change in net working capital	(522.4)	152.9
Cash flow from operating activities	(581.7)	103.6
Investing activities		
Acquisition of intangible assets	58.4	53.1
Acquisition of tangible assets	0.0	0.0
Cash flow from investing activities	58.4	53.1
Financing acitivities		
Change in equity	340.3	1.7
Change in interest bearing debt	0.4	0.7
Cash flow from financing activities	340.7	2.3
Cash flow for the period	(182.7)	159.0
Cash and cash equivalents at the beginning of the period	287.7	128.7
Cash and cash equivalents at end of the period	105.1	287.7



Basis of reporting

Basis of preparation

- BioCirc (the "Group") consists of BioCirc Group Holding ApS and its subsidiaries. BioCirc Group Holding ApS (the "Parent Company") is a privately held company incorporated in Denmark. The Company's registered office is at Amaliegade 22, 1256 Copenhagen.
- BioCirc Group Holding ApS financial statements have been prepared in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (large).
- The consolidated financial statement for Biocirc Group Holding ApS have been prepared in accordance with IFRS accounting standards.
- The financial statements are presented in Danish Kroner, which is the functional currency of the Company. The reporting period covers 1 January 2025 to 30 June 2025. Our H1 report was published on 30 June 2025.

Profit and Loss (P&L) items

- Revenue consists of sales of gas, certificates, raw materials for biogas plants, grants received, project revenue from EPC activities and other revenue
- **Direct costs** include costs related to biomass and energy consumption, transportation, production personnel, repair and maintenance, and other operating expenses. Project costs relate to the Group's EPC activity in Germany
- Personnel costs comprise wages and salaries, and social security contributions, pension contributions, etc. for the Group's employees which are not allocated directly to direct costs
- Administration and sales include expenses related to the Group's activities, including expenses for premises, stationery and office supplies, marketing costs, etc.

- Other costs include, among others, management fees
- Depreciation and amortisation relates to property, plant and equipment, and intangible assets
- Net financial loss comprises interest expenses on bank debt, finance leases, foreign exchange gains/losses, tax surcharge under the Danish Tax prepayment scheme, commissions, fees, and interest income, etc.

Balance sheet items

- **Intangible assets** consist of goodwill. Goodwill is amortised on a straight-line basis over its estimated useful life, which is determined by management's experience in each business area. The amortisation period ranges from 10 to 19 years
- Property, plant, and equipment consist of tangible assets used in the company's operations, such as buildings and machinery. The depreciation period ranges from 3 to 40 years
- Inventory include biomass, raw materials, consumables, direct labour costs, and indirect production costs
- Trade receivables represent amounts due from the sale of gas and certificates
- Other receivables include VAT receivables and other receivables etc.
- Cash comprises cash in hand and bank deposits
- Provisions include deferred tax relating to all temporary differences between the carrying amount and the tax based vaue of assets and liabilities and other provisions
- Interest bearing debt consists of morgage debt, bank loans, bond debt and lease liabilities
- Trade payables relates to the amounts owed to suppliers for goods or services
- **Deferred income** comprises energy saving funds received ("Energisparetilskud") for recognition in subsequent financial years
- Other payables consist of corporate tax payable, VAT payable, and other outstanding payables



BioCirc Group Holding ApS Amaliegade 22 1256 København Denmark

Shaping the Green Energy Transition